Pneumocystis jirovecii (Pneumocystis pneumonia)

3,319views

Pneumocystis jirovecii (Pneumocystis pneumonia)

E Respi

E Respi

Upper respiratory tract infection
Upper respiratory tract infections: Clinical sciences
Rhinovirus
Anatomy of the nose and paranasal sinuses
Sinusitis
Streptococcus pneumoniae
Nasal, oral and pharyngeal diseases: Pathology review
Anatomy of the external and middle ear
Anatomy clinical correlates: Ear
Otitis media
Otitis media and externa (pediatrics): Clinical sciences
Haemophilus influenzae
Moraxella catarrhalis
Streptococcus pyogenes (Group A Strep)
Acute group A streptococcal infections and sequelae (pediatrics): Clinical sciences
KIF1A-associated neurological disorder: Year of the Zebra
Poststreptococcal glomerulonephritis
Coxsackievirus
Acute rheumatic fever and rheumatic heart disease: Clinical sciences
Epstein-Barr virus (Infectious mononucleosis)
Adenovirus
Retropharyngeal and peritonsillar abscesses
Pharyngitis, peritonsillar abscess, and retropharyngeal abscess (pediatrics): Clinical sciences
Croup
Human parainfluenza viruses
Croup and epiglottitis: Clinical sciences
Respiratory syncytial virus
Bronchiolitis: Clinical sciences
Immunizations (adult): Clinical sciences
Influenza virus
Neuraminidase inhibitors
Influenza: Clinical sciences
The flu vaccine: Information for patients and families
COVID-19: Clinical sciences
Obstructive lung diseases: Pathology review
Asthma
Asthma: Clinical sciences
Tobacco dependence
Tobacco use: Clinical sciences
Approach to a cough (acute): Clinical sciences
Approach to a cough (subacute and chronic): Clinical sciences
Approach to dyspnea: Clinical sciences
Approach to chest pain: Clinical sciences
Approach to a fever: Clinical sciences
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Tuberculosis (pulmonary): Clinical sciences
Tuberculosis (extrapulmonary and latent): Clinical sciences
Antituberculosis medications
Cystic fibrosis: Pathology review
Cystic fibrosis
Cystic fibrosis and primary ciliary dyskinesia: Clinical sciences
Reading a chest X-ray
Chest X-ray interpretation: Clinical sciences
Pneumocystis jirovecii (Pneumocystis pneumonia)
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome
Acute respiratory distress syndrome: Clinical sciences
Neonatal respiratory distress syndrome: Clinical sciences
Deep vein thrombosis and pulmonary embolism: Pathology review
Pulmonary embolism
Pulmonary embolism: Clinical sciences

Assessments

Flashcards

0 / 36 complete

USMLE® Step 1 questions

0 / 3 complete

High Yield Notes

12 pages

Flashcards

Pneumocystis jirovecii (Pneumocystis pneumonia)

0 of 36 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 3 complete

A 65-year-old man comes to the emergency department for evaluation of three weeks of a dry cough, shortness of breath, and fever. The patient has noted significant weight loss (10 lb) over the last nine months. Past medical history is significant for dyslipidemia, HIV, and CMV retinitis. The patient is noncompliant with antiretroviral therapy. Current medications include tenofovir-emtricitabine and dolutegravir and atorvastatin. The patient is sexually active with men and uses condoms inconsistently. The patient does not use intravenous drugs, alcohol, or tobacco. The patient owns two parrots and a cat. Temperature is 38.11°C (100.0°F), pulse is 121/min, respirations are 26/min, and blood pressure is 98/75 mmHg, SpO2 is 89% on room air. The patient is using accessory muscles of respiration. Physical examination reveals anterior and posterior cervical lymphadenopathy. Oral examination reveals white, mucosal plaques on the lateral aspect of the tongue that cannot be scraped off with a tongue depressor. Rales are present in the bilateral anterior lung fields. A CT of the patient’s chest is depicted below.  CD4 count is 157 cells/microL. Which of the following organisms is the most likely etiology of this patient’s current disease process?
 
Radiopedia

External References

First Aid

2024

2023

2022

2021

Pneumocystis jirovecii p. , 151

dapsone p. 191

HIV-positive adults p. 174

immunocompromised patients p. 176

silver stain for p. 123

TMP-SMX p. 191

AIDS (acquired immunodeficiency syndrome)

Pneumocystis jirovecii p. , 151

Atovaquone

for Pneumocystis jirovecii p. , 151

Dapsone p. 191

Pneumocystis jirovecii p. , 151

HIV (human immunodeficiency virus) p. 173

Pneumocystis jirovecii p. , 151

Immunocompromised patients

Pneumocystis jirovecii p. , 151

Pneumonia p. 701

Pneumocystis jirovecii p. , 151

TMP-SMX p. 191

for Pneumocystis jirovecii p. , 151

Pneumocystis spp. p. 115

Pneumocystis pneumonia

HIV-positive adults p. 174

prophylaxis p. 194

Summary

Pneumocystis jirovecii sometimes referred to as Pneumocystis carinii, is a fungus known to cause a severe lung infection called Pneumocystis pneumonia (PCP). PCP commonly affects individuals with weakened immune systems, such as people with HIV/AIDS, cancer patients receiving chemotherapy, or people taking immunosuppressive drugs. Symptoms of PCP can include fever, cough, shortness of breath, and difficulty breathing. Treatment typically involves antifungal medications, such as trimethoprim-sulfamethoxazole, pentamidine, or dapsone.